Bairdon Biohaven (BHVN): 'e think case studies from today's presentation answers the major question lingering for BHV-1400'
Tweet Send to a Friend
Baird analyst Brian Skorney reiterated an Outperform rating and $42.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
